Low-toxin Clostridioides difficile RT027 strains exhibit robust virulence

References

• Smits WK, Lyras D, Lacy DB, et al. Clostridium difficile infection. Emergency General Surgery: A Practical Approach. Nat Rev Dis Primers. 2016;2(1):16020–16020.
   PubMed Web of Science ®Google Scholar
• CDC. Antibiotic resistance threats in the United States. Atlanta, GA: The Centers for Disease Control and Prevention; 2019. p. 114-114.
   Google Scholar
• Aktories K, Schwan C, Jank T. Clostridium difficile toxin biology. Annu Rev Microbiol. 2017;71(1):281–307.
   PubMed Web of Science ®Google Scholar
• Kuehne SA, Cartman ST, Heap JT, et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010;467(7316):711–713.
   PubMed Web of Science ®Google Scholar
• He M, Miyajima F, Roberts P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2013;45(1):109–113.
   PubMed Web of Science ®Google Scholar
• Orozco-Aguilar J, Alfaro-Alarcón A, Acuña-Amador L, et al. In vivo animal models confirm an increased virulence potential and pathogenicity of the NAP1/RT027/ST01 genotype within the Clostridium difficile MLST clade 2. Gut Pathog. 2020;12:45–45.
   PubMed Web of Science ®Google Scholar
• Lanis JM, Heinlen LD, James JA, et al. Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog. 2013;9(8):e1003523–e1003523.
   PubMed Web of Science ®Google Scholar
• Collins J, Robinson C, Danhof H, et al. Dietary trehalose enhances virulence of epidemic Clostridium difficile. Nature. 2018 Jan 18;553(7688):291–294.
   PubMed Web of Science ®Google Scholar
• Merrigan M, Venugopal A, Mallozzi M, et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol. 2010 Oct;192(19):4904–4911.
   PubMed Web of Science ®Google Scholar
• Boone JH, Archbald-Pannone LR, Wickham KN, et al. Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality. Eur J Clin Microbiol Infect Dis. 2014;33(6):1045–1051.
   PubMed Web of Science ®Google Scholar
• Anikst VE, Gaur RL, Schroeder LF, et al. Organism burden, toxin concentration, and lactoferrin concentration do not distinguish between clinically significant and nonsignificant diarrhea in patients with Clostridium difficile. Diagn Microbiol Infect Dis. 2016 Apr;84(4):343–346.
   PubMed Web of Science ®Google Scholar
• Guerrero DM, Chou C, Jury LA, et al. Clinical and infection control implications of Clostridium difficile infection with negative enzyme immunoassay for toxin. Clin Infect Dis. 2011;53(3):287–290.
   PubMed Web of Science ®Google Scholar
• Mawer DPC, Eyre DW, Griffiths D, et al. Contribution to Clostridium difficile transmission of symptomatic patients with toxigenic strains who are fecal toxin negative. Clinical Infect Dis. 2017;64(9):1163–1170.
   PubMed Web of Science ®Google Scholar
• Hamo Z, Azrad M, Fichtman B, et al. The cytopathic effect of different toxin concentrations from different Clostridioides difficile sequence types strains in vero cells. Front Microbiol. 2021;12:763129–763129.
   PubMed Web of Science ®Google Scholar
• Tamez-Torres KM, Torres-González P, Leal-Vega F, et al. Impact of Clostridium difficile infection caused by the NAP1/RT027 strain on severity and recurrence during an outbreak and transition to endemicity in a Mexican tertiary care center. Int J Infect Dis. 2017;65:44–49.
   PubMed Web of Science ®Google Scholar
• Rao K, Micic D, Natarajan M, et al. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin Infect Dis. 2015;61(2):233–241.
   PubMed Web of Science ®Google Scholar
• Fang FC, Polage CR, Wilcox MH. Point-counterpoint: what is the optimal approach for detection of Clostridium difficile infection? J Clin Microbiol. 2017;55(3):670 LP-680.
   Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987–994.
   PubMed Web of Science ®Google Scholar
• Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175(11):1792–1801.
   PubMed Web of Science ®Google Scholar
• Merrigan M, Venugopal A, Mallozzi M, et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol. 2010;192:4904–4911.
   PubMed Web of Science ®Google Scholar
• Chu M, Mallozzi MJG, Roxas BP, et al. A Clostridium difficile cell wall glycopolymer locus influences bacterial shape, polysaccharide production and virulence. PLoS Pathog. 2016;12(10):e1005946–e1005946.
   PubMed Web of Science ®Google Scholar
• Janezic S, Strumbelj I, Rupnik M. Use of modified PCR ribotyping for direct detection of Clostridium difficile ribotypes in stool samples. J Clin Microbiol. 2011;49(8):3024–3025.
   PubMed Web of Science ®Google Scholar
• Pituch H, Rupnik M, Obuch-Woszczatyński P, et al. Detection of binary-toxin genes (cdtA and cdtB) among Clostridium difficile strains isolated from patients with C. difficile-associated diarrhoea (CDAD) in Poland. J Med Microbiol. 2005;54:143–147.
   PubMed Web of Science ®Google Scholar
• Fawley WN, Knetsch CW, MacCannell DR, et al. Development and validation of an internationally-standardized, high-resolution capillary Gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile. PloS one. 2015;10(2):e0118150–e0118150.
   PubMed Web of Science ®Google Scholar
• Rupnik M, Braun V, Soehn F, et al. Characterization of polymorphisms in the toxin A and B genes of Clostridium difficile. FEMS Microbiol Lett. 2006;148(2):197–202.
   Google Scholar
• CLSI. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. 8th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
   Google Scholar
• Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature. 2009;458(7242):1176–1179.
   PubMed Web of Science ®Google Scholar
• Sambol Susan P, Merrigan Michelle M, Janet KT, et al. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis. 2002;186(12):1781–1789.
   PubMed Web of Science ®Google Scholar
• Razaq N, Sambol S, Nagaro K, et al. Infection of hamsters with historical and epidemic BI types of Clostridium difficile. J Infect Dis. 2007;196(12):1813–1819.
   PubMed Web of Science ®Google Scholar
• Reeves AE, Theriot CM, Bergin IL, et al. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile infection. Gut Microbes. 2011;2(3):145–158.
   PubMed Web of Science ®Google Scholar
• Zuo G, Hao B. CVTree3 web server for whole-genome-based and alignment-free prokaryotic phylogeny and taxonomy. Genom Proteom Bioinf. 2015 Oct;13(5):321–331.
   PubMed Web of Science ®Google Scholar
• Letunic I, Bork P. Interactive Tree Of Life (iTOL) v4: recent updates and new developments. Nucleic Acids Res. 2019 Jul 2;47(W1):W256–w259.
   PubMed Web of Science ®Google Scholar
• McQuade R, Roxas B, Viswanathan VK, et al. Clostridium difficile clinical isolates exhibit variable susceptibility and proteome alterations upon exposure to mammalian cationic antimicrobial peptides. Anaerobe. 2012;18(6):614–620.
   PubMed Web of Science ®Google Scholar
• Pantaléon V, Soavelomandroso AP, Bouttier S, et al. The Clostridium difficile protease Cwp84 modulates both biofilm formation and cell-surface properties. PLoS ONE. 2015;10(4):e0124971–e0124971.
   PubMed Web of Science ®Google Scholar
• Lyerly DM, Wilkins TD. Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol. 1986 Mar;23(3):622–623.
   PubMed Web of Science ®Google Scholar
• Yuhashi K, Yagihara Y, Misawa Y, et al. Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients. Infect Drug Resist. 2016;9:93–99.
   PubMed Web of Science ®Google Scholar
• Murad YM, Perez J, Ybazeta G, et al. False negative results in Clostridium difficile testing. BMC Infect Dis. 2016;16(1):430–430.
   PubMed Web of Science ®Google Scholar
• Majumdar A, Govind R. Regulation of Clostridioides difficile toxin production. Curr Opin Microbiol. 2022;65:95–100.
   PubMed Web of Science ®Google Scholar
• Feltis BA, Wiesner SM, Kim AS, et al. Clostridium difficile toxins A and B can alter epithelial permeability and promote bacterial paracellular migration through HT-29 enterocytes. Shock. 2000;14(6):629–634.
   PubMed Web of Science ®Google Scholar
• George RH, Symonds JM, Dimock F, et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J. 1978 Mar 18: 1(6114):695.
   PubMed Web of Science ®Google Scholar
• Hecht G, Koutsouris A, Pothoulakis C, et al. Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology. 1992;102(2):416–423.
   PubMed Web of Science ®Google Scholar
• Hecht G, Pothoulakis C, LaMont JT, et al. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest. 1988;82(5):1516–1524.
   PubMed Web of Science ®Google Scholar
• Erb S, Frei R, Strandén AM, et al. Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients. Clin Microbiol Infect. 2015;21(11):998.e9-998.e15.
   PubMed Web of Science ®Google Scholar
• Knight DR, Elliott B, Chang BJ, et al. Diversity and evolution in the genome of Clostridium difficile. Clin Microbiol Rev. 2015;28(3):721–741.
   PubMed Web of Science ®Google Scholar
• Edwards AN, Anjuwon-Foster BR, McBride SM. RstA is a major regulator of Clostridioides difficile toxin production and motility. mBio. 2019;10(2):e01991–18.
   PubMed Web of Science ®Google Scholar
• Darkoh C, DuPont HL, Norris SJ, et al. Toxin synthesis by Clostridium difficile is regulated through quorum signaling. mBio. 2015;6(2):e02569–14.
   PubMed Web of Science ®Google Scholar
• Antunes A, Camiade E, Monot M, et al. Global transcriptional control by glucose and carbon regulator CcpA in Clostridium difficile. Nucleic Acids Res. 2012;40(21):10701–10718.
   PubMed Web of Science ®Google Scholar
• Aubry A, Hussack G, Chen W, et al. Modulation of toxin production by the flagellar regulon in Clostridium difficile. Infect Immun. 2012;80(10):3521–3532.
   PubMed Web of Science ®Google Scholar
• Saujet L, Monot M, Dupuy B, et al. The key sigma factor of transition phase, SigH, controls sporulation, metabolism, and virulence factor expression in Clostridium difficile. J Bacteriol. 2011;193(13):3186–3196.
   PubMed Web of Science ®Google Scholar
• Dineen SS, Villapakkam AC, Nordman JT, et al. Repression of Clostridium difficile toxin gene expression by CodY. Mol Microbiol. 2007;66:206–219.
   PubMed Web of Science ®Google Scholar
• Laabei M, Uhlemann AC, Lowy FD, et al. Evolutionary trade-offs underlie the multi-faceted virulence of staphylococcus aureus. PLoS Biol. 2015;13(9):e1002229.
   PubMed Web of Science ®Google Scholar
• Hollands A, Pence MA, Timmer AM, et al. Genetic switch to hypervirulence reduces colonization phenotypes of the globally disseminated group A streptococcus M1T1 clone. J Infect Dis. 2010;202(1):11–19.
   PubMed Web of Science ®Google Scholar